News und Analysen
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share of Class
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 5, 2022, following the release of its first quarter
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new
DGAP-News: MicroVision Inc.: MicroVision to Announce First Quarter 2022 Results on April 27, 2022
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis’ senior management will
STAAR Surgical to Report First Quarter Results on May 4, 2022
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown Portsmouth, New Hampshire
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April
Simulations Plus to Present at the Berenberg Discover AI Seminar
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be
Agilent Joins the National Institute for Innovation in Manufacturing to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) announced that it has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL). Membership in NIIMBL demonstrates
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Humana’s Impact Report Focuses on Building Trust and Transparency in Journey to Health Equity
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, released its 2021 Impact Report, which highlights the company’s continued commitment to its Environment
Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2022 results on Tuesday, May 3, 2022, after the close of the market. Acadia will conduct a
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2022 financial results on Wednesday, May 4th, before the market opens. A conference call has been scheduled to
Humana Expands National Commitment to Affordable Housing With Additional $25 Million Investment
As part of its national commitment to improve housing stability for vulnerable members and communities, Humana Inc. (NYSE: HUM) today announced an additional $25 million investment in three
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic
Humana Throws the First Pitch Event to Connect Minority-Owned Businesses to Top Humana Suppliers
The Supplier Diversity Team of Humana Inc. (NYSE: HUM) hosted the First Pitch, a virtual forum where participants from the Humana Mentor Protégé Program had the opportunity to pitch their business
Pfizer Names David M. Denton Chief Financial Officer
Pfizer Inc. (NYSE: PFE) today announced that David M. Denton will join the Company as Chief Financial Officer (CFO) and Executive Vice President effective May 2, 2022. Mr. Denton will be a member
NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of over 125 studies enabled by